

1 **Original Article**

2
3
4 **Role of paraoxonase-1 (PON-1) as a diagnostic marker for feline infectious peritonitis**
5 **(FIP)**

6
7 S. Meazzi^{a,b}, S. Paltrinieri^{a,b}, S. Lauzi^{a,b}, A. Stranieri^{a,b,*}, I. Brentali^a, R. Ferriani^c, G. Rossi^d,
8 A. Giordano^{a,b}

9
10
11 ^a *Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20122, Milano*
12 *(MI), Italy*

13 ^b *Veterinary Teaching Hospital, University of Milan, via dell'Università, 6, 26900 Lodi (LO),*
14 *Italy*

15 ^c *Ospedale Veterinario San Francesco, Via Isaac Newton 6, CAP Milano (MI), Italy*

16 ^d *College of Veterinary Medicine, School of Veterinary and Life Science, Murdoch University,*
17 *90 South Street, Murdoch, 6150, Western Australia, Australia*

18
19
20
21
22 * Corresponding author. Tel. +39 0250334174

23 E-mail address: angelica.stranieri@unimi.it

24

25 **Abstract**

26 Feline infectious peritonitis (FIP) is characterized by a huge inflammatory response
27 accompanied by oxidative stress. Paraoxonase-1 (PON-1) is a liver enzyme that circulates in
28 blood bound to high density lipoproteins. Its hydrolytic properties have been associated with
29 an antioxidant activity and its role as negative acute phase reactant has been investigated in
30 people and animals. A paraoxon based method has been validated to measure feline serum
31 PON-1 activity, allowing to observe a negative correlation between PON-1 activity and acute
32 phase proteins concentration. . The aim of this study was to investigate the usefulness of
33 PON-1 as a biomarker able to discriminate FIP from other diseases with similar clinical signs.
34 Of 159 cats enrolled, 71 were healthy, 34 were affected by FIP and 54 were affected by other
35 clinical conditions with signs consistent with FIP. PON-1 activity was lower ($P < 0.0001$) in
36 cats with FIP (median= 26.55 U/L; min – max= 5.40 – 78.20 U/L) compared to healthy (87.5
37 U/L; 46.60 – 215.50 U/L) and NON FIP cats (57.90 U/L; 3.80 – 122.60 U/L). The receiver
38 operating characteristic curve allowed to determine the threshold that maximizes the
39 performance of PON-1 in predicting FIP: a value of 51.40 U/L yielded 82% sensitivity and
40 specificity and a positive likelihood ratio of 4.65. A value of 24.90 U/L maximizes specificity
41 (97.6%) and increases the likelihood ratio up to 18.38, making PON-1 a good confirmatory
42 test for FIP. Using these thresholds, serum PON-1 activity showed optimal diagnostic
43 performances in discriminating FIP affected cats from cats with other inflammatory
44 conditions.

45 *Keywords:* Acute phase protein; Biomarker; Feline infectious peritonitis; Paraoxonase-1

46 **Introduction**

47 Feline infectious peritonitis (FIP) is a systemic fatal disease affecting mostly young cats
48 and sustained by a virulent biotype of the feline coronavirus (FCoV) (Pedersen, 2014a). FCoV
49 are usually found in the intestinal tract and named “less virulent FCoV” (previously called feline
50 enteric coronavirus, FECV) (Kennedy, 2020). However, during viral replication, a mutated
51 variant, called FIP-associated FCoV (FIPV) may be generated (Pedersen, 2014a). Although
52 both viral biotypes can spread systemically, only the FIPV is able to induce FIP. Depending on
53 the host immune response, clinical presentation of FIP can include effusions in one or several
54 body cavities (effusive or wet form), or granulomatous lesions in different organs (non-effusive
55 or dry form) (Pedersen, 2014a).

56

57 The *in vivo* diagnosis of FIP is challenging, especially in dry forms, despite the
58 availability of several diagnostic tests (Tasker, 2018). The definitive diagnosis can only be
59 achieved by demonstrating the presence of intralésional FCoV through immunohistochemistry,
60 usually on *post-mortem* biopsies (Pedersen, 2014b; Tasker, 2018). *In vivo*, the suspicion of FIP
61 relies on signalment, clinical history and laboratory data (Addie et al., 2009; Stranieri et al.,
62 2017; Tasker, 2018). In wet forms, the effusions analyses including macroscopic appearance,
63 cytological features and instrumental findings, can be very helpful for FIP diagnosis (Addie et
64 al., 2009; Giordano et al., 2015; Saunders, 2016; Tasker, 2018). Despite spike gene mutations
65 may be indicative of FIP-associated FCoV, RT-PCR is not able to distinguish the two biotypes
66 (Felten and Hartmann, 2019). However, a positive result may support the clinical suspicion of
67 FIP, while a negative result cannot rule out the disease (Kipar and Meli, 2014; Saunders, 2016;
68 Felten et al., 2017, Stranieri et al., 2018). The increase of alpha-1-acid glycoprotein (AGP) on
69 serum is highly suggestive of FIP but results based on a radial immunodiffusion assay are prone

70 to subjective interpretation and require at least two days to be generated (Paltrinieri et al., 2007;
71 Giori et al., 2011; Tasker, 2018).

72

73 Paraoxonase-1 (PON-1) belongs to a group of enzymes (paraoxonases) and it can
74 metabolize the organophosphate paraoxon. PON-1 is a glycoprotein, synthesized by the liver,
75 that circulates in blood associated with high density lipoproteins (HDL) particles, specifically
76 the apolipoprotein-1 (Furlong et al., 2016; Shunmoogam et al., 2018). During inflammation,
77 especially when associated with a marked oxidative stress, the HDL particles lose the
78 apolipoprotein-1 and many associated enzymes, including PON-1, that are replaced by serum
79 amyloid A and ceruloplasmin (Khovidhunkit et al., 2004; Rossi et al., 2020). Moreover, hepatic
80 synthesis of PON-1 is inhibited during inflammation (Feingold et al., 1998), suggesting that
81 PON-1 acts as a negative acute phase reactant. PON-1 activity decreases during severe
82 inflammatory processes in humans as well as in several animal species, including cats
83 (Giordano et al., 2013; Rossi et al., 2013; Rossi et al., 2020). Cats are more susceptible than
84 other species to oxidative injuries (Feingold et al., 1998). A recent study has demonstrated the
85 intimate relationship between inflammation and oxidative stress during feline infectious
86 diseases (Tecles et al., 2015). Despite lower values of PON-1 activity were expected in cats
87 affected by FIP, in the cited study no differences in PON-1 activity between cats with FIP or
88 other diseases were found. Moreover, PON-1 activity was measured by Tecles and colleagues
89 using a method different from the paraoxon based method, which was recently validated in cats
90 (Rossi et al., 2020). This recent validation study also revealed a negative correlation between
91 serum AGP and PON-1, supporting the role of this enzyme as negative acute phase reactant.

92

93 The aim of the present study was to evaluate the potential of PON-1 in discriminating
94 FIP affected cats within a group of animals with clinical signs consistent with the disease and
95 to establish its usefulness as an *in vivo* biomarker.

96

97 **Materials and methods**

98 *Animals and Sample Collection*

99 All the animals were submitted for clinical examinations to the Veterinary Teaching
100 Hospital (University of Milan) or to private practitioners. Both clinically healthy cats and cats
101 with clinical signs consistent with FIP, regardless of the final diagnosis, were enrolled.

102

103 Inclusion criteria for the entire caseload were at least the results of the complete blood
104 cell count and a serum biochemistry panel (including creatinine, urea, total protein, alanine
105 aminotransferase, alkaline phosphatase and glucose) and the availability of serum leftover from
106 the routine diagnostic procedures (at least 150 μ L). Serum leftover was frozen at -20°C until
107 further analyses.

108

109 The cats were divided in two groups: sick group and control group. Inclusion criteria
110 for the control group (CNTR) were a normal physical examination and the absence of laboratory
111 abnormalities. For sick cats, the inclusion criteria were the presence of one or more clinical
112 signs commonly associated with FIP, namely: effusions, hyperthermia, anorexia, weight loss,
113 depression, jaundice, neurological or ocular signs (Tasker, 2018).

114

115 Moreover, the sick group was divided in FIP and NON FIP groups. Specifically, the
116 diagnosis of FIP (FIP group) was achieved by positive IHC revealing FCoV antigen within
117 intra-lesional macrophages on *post mortem* biopsies, using the IHC protocol employed in

118 previous studies (Stranieri et al., 2020). When the *post mortem* examination was not authorized
119 by the owners, the diagnosis of FIP was achieved based on signalment, clinical signs and at
120 least five of the following laboratory changes consistent with FIP (lymphopenia;
121 hyperproteinemia; hypoalbuminemia; low albumin/globulin ratio; electrophoretic peaks in α -2
122 and γ region; serum AGP higher than 1.5 mg/mL; positive RT-PCR on blood, tissues or
123 effusions and a delta total nucleated cells measured by Sysmex XT-2000iV [Δ TNC] higher than
124 2.5 on effusions along with consistent cytology) along with the worsening of the clinical
125 conditions that always led to spontaneous death or to humane euthanasia (Paltrinieri et al., 2007;
126 Giordano et al., 2013).

127

128 Further, cats belonging to the FIP group were divided according to the clinical form of
129 the disease, namely effusive (WET FIP) and non-effusive FIP (DRY FIP) or according to the
130 type of diagnostic approach, namely FIP confirmed by IHC (CONFIRMED FIP) or FIP
131 suspected based on clinical and clinical-pathological results but not confirmed by IHC
132 (PRESUMPTIVE FIP).

133

134 Diseases of cats included in the NON FIP group were diagnosed with diagnostic
135 imaging (ultrasound, MRI, TC) and laboratory data confirming the presence of a specific
136 clinical condition other than FIP.

137

138 The samples had been collected for diagnostic purposes according to standard veterinary
139 procedures. Therefore, according to the regulations of our institution, a formal approval of the
140 Institutional Ethical Committee was not required (EC decision 29 Oct 2012, renewed with the
141 protocol n° 02-2016).

142

143 *Measurement of PON-1 activity*

144 PON-1 activity was measured using a paraoxon based method, already validated in cats
145 (Rossi et al., 2020) on an automated spectrophotometer (Cobas Mira, Roche Diagnostic),
146

147 *Statistical Methods*

148 Statistical analyses were performed using the software Analyse-it for Microsoft Excel
149 (Analyse-it Software Ltd). Specifically, differences in PON-1 activity among groups (CNTR,
150 FIP and NON FIP) were evaluated using the Kruskal-Wallis test, followed, in case of
151 significant differences, by the Mann-Whitney *U* test.
152

153 The comparison between the FIP subgroups (namely WET FIP vs DRY FIP and
154 CONFIRMED FIP vs PRESUMPTIVE FIP) was performed using Mann-Whitney *U* test. PON-
155 1 activity of each FIP subgroup was compared with those of NON FIP and CNTR groups using
156 the Kruskal-Wallis test, followed, in case of significant differences, by the Mann-Whitney *U*
157 test. Statistical significance was set at $P < 0.05$.
158

159 Finally, to evaluate the diagnostic power of PON-1 activity in discriminating FIP
160 affected cats, sensitivity and specificity were calculated using standard formulas (Christenson,
161 2007). Moreover, positive (LR+) and negative (LR-) likelihood ratios were calculated using the
162 following formulae: $LR+ = (\text{sensitivity})/(\text{1-specificity})$ and $LR- = (\text{1-sensitivity})/(\text{specificity})$.
163 A receiver operating characteristic curve (ROC) was built by plotting sensitivity vs 1-
164 specificity. The area under the curve (AUC) was calculated and the ROC curve was used to
165 determine clinically relevant thresholds (Gardner and Greiner, 2006).
166

167 **Results**

168 *Group composition*

169 A total of 159 cats was enrolled. Among those, 71 were healthy (CNTR group), 54 were
170 affected by disease other than FIP (NON FIP group) and 34 were affected by FIP (FIP group).
171 Details about cats signalment are reported in Table 1.

172

173 In the NON FIP group, 47 cats presented an effusion (19 peritoneal, 30 pleural, 6
174 pericardial, 8 cats had bi-cavitary effusions). The remaining 7 cats had hyperthermia and
175 lethargy ($n = 4$) and neurological or ocular signs ($n = 3$). Most of the cats had a definitive
176 diagnosis of neoplasia ($n = 21$), followed by cardiogenic effusion ($n = 7$), chylothorax ($n = 6$),
177 septic effusion ($n = 7$), infectious diseases ($n = 4$), IMHA ($n = 2$), pleuritis ($n = 1$), intestinal
178 occlusion ($n = 1$), traumatism ($n = 3$) or hepatic lipidosis ($n = 2$).

179

180 The FIP group was composed by 27 cats with effusions (21 peritoneal, 8 pleural, 2
181 pericardial. Four cats showed bi- or tri-cavitary effusion). Seven cats were affected by the dry
182 form with the presence of neurological or ocular signs ($n = 4$) or non-specific signs
183 (hyperthermia, jaundice, lethargy and vomiting, $n = 3$). In 19 cases, the definitive diagnosis was
184 achieved through IHC (CONFIRMED FIP). In the remaining 15 cases, FIP was diagnosed
185 according to laboratory abnormalities highly consistent with FIP, along with the severe clinical
186 conditions that always ended with spontaneous death or euthanasia (PRESUMPTIVE FIP)
187 (Table 2).

188

189 *Difference in PON-1 activity among CNTR, FIP and NON FIP*

190 PON-1 activity was significantly different among the three groups ($P < 0.0001$).
191 Specifically, PON-1 activity was significantly lower in FIP cats (median= 26.55 U/L; min –
192 max= 5.40 – 78.20 U/L) than in CNTR (87.5 U/L; 46.60 – 215.50 U/L) and NON FIP cats

193 (57.90 U/L; 3.80 – 122.60 U/L) ($P < 0.0001$ in both cases) (Fig. 1). Cats belonging to the NON
194 FIP group had values of PON-1 activity significantly lower than the CNTR cats ($P < 0.0001$).

195

196 *Comparison between presumptive FIP and confirmed FIP*

197 The values recorded in the PRESUMPTIVE FIP subgroup (30.60 U/L; 5.40 – 68.10
198 U/L) were not significantly different from the CONFIRMED FIP subgroup (25.70 U/L; 6.30 –
199 78.20 U/L) ($P = 0.61$). Conversely, the results of both subgroups were significantly lower
200 compared with NON FIP and CNTR groups ($P < 0.0001$) (Fig.2).

201

202 *Comparison between effusive and non-effusive FIP*

203 The cats with effusive FIP (WET FIP) had a lower PON-1 activity (23.20 U/L; 5.40 – 71.50
204 U/L) compared with those with DRY FIP (48.00 U/L; 15.10 – 78.20 U/L) ($P = 0.035$) (Fig. 3).
205 PON-1 activity was significantly lower in cats with the effusive FIP compared to NON FIP and
206 CNTR group ($P < 0.0001$). Nevertheless, cats with the non-effusive FIP showed significantly
207 lower PON-1 activity compared with the CNTR group ($P = 0.0003$), but values were not
208 different from those of the NON FIP group ($P = 0.44$).

209

210 *Diagnostic performance of PON-1*

211 The analysis of ROC curve highlighted a statistical difference from the no-discrimination
212 line ($P < 0.0001$), with an AUC of 88.7% (CI 95% = 0.83 – 0.94) (Fig. 4). Based on the ROC
213 curve, the threshold that maximizes the diagnostic power of the test, providing equal sensitivity
214 and specificity, corresponds to a PON-1 activity of 51.40 U/L (Se and Sp = 82%).

215

216 **Discussion**

217 PON-1 acts as a negative acute phase reactant in cats, similarly to other species (Giordano
218 et al., 2013; Rossi et al., 2013; Rossi et al., 2020). From this perspective, the lower PON-1
219 activity observed in the FIP group compared to the other groups was not surprising, especially
220 given the strong inflammatory response and the oxidative stress that characterize FIP (Regan et
221 al., 2009; Tecles et al., 2015). Pro-inflammatory cytokines such as IL-6, TNF- α and IL-1 β ,
222 (Montorfano et al., 2014) enhance the oxidative stress via macrophages and neutrophils
223 respiratory burst activity that ends in the production of reactive oxygen species (ROS) (Kumar
224 et al., 2010). Indeed, during FIP, pro-inflammatory cytokines increase the release of the bone
225 marrow neutrophils reservoir and decrease their apoptotic rate (Paltrinieri et al., 2008; Takano
226 et al., 2009; Paltrinieri et al., 2020). The massive recruitment of the neutrophilic component, in
227 turn, enhances the oxidative stress through the release of strong oxidant components. A
228 previous study had highlighted how PON-1 activity decreases in cats affected by infectious
229 diseases including FIP (Tecles et al., 2015). This may likely occur due to its dual role as
230 negative acute phase reactant and antioxidant compound, as demonstrated in other species
231 (Rossi et al., 2014; Ruggerone et al., 2020). Indeed, PON-1 tends to decrease significantly in
232 those inflammatory processes that involve a strong oxidative stress. So, a lower PON-1 activity
233 value was expected in FIP affected cats, as observed in the present study.

234

235 In the NON FIP group, PON-1 activity resulted significantly higher than in FIP cats, but
236 lower than in CNTR cats. This result may depend on the high number of cats with neoplasia,
237 since one anti-tumoral mechanism is the production of ROS by macrophages (Kumar et al.,
238 2010). Additionally, in some neoplasia (e.g. renal carcinoma), the neoplastic cells themselves
239 produce ROS, to enhance their survival (Toyokuni et al., 1995). However, it is unlikely that
240 neoplasia could cause the same systemic effect of a strong inflammation as FIP. The lowest
241 values of PON-1 activity in the NON FIP group were recorded in cats with septic effusions.

242 Sepsis determine a huge inflammatory response, often associated with massive oxidative
243 damage, thus possibly inducing a PON-1 decrease (Bojic et al., 2014).

244

245 A possible limitation of the study is that FIP was IHC only in 19/34 cats of the FIP
246 group. Nevertheless, FIP was the most likely diagnosis in all the cats of this group, based on
247 clinical and laboratory findings. Moreover, PON-1 activity did not significantly differ in cats
248 with confirmed or presumptive FIP and, in both subgroups, it was lower than that of NON FIP
249 and CNTR cats. This result further supports FIP in those cats in which IHC was not performed.

250

251 In the effusive form, PON-1 activity was decreased compared to the non-effusive form.
252 This result is consistent with the higher inflammatory component of the effusive form. Indeed,
253 in the non-effusive form, a partially protective cellular mediated immune response causes the
254 destruction of infected monocytes and, in turn, a lower viral spread (Pedersen, 2014a). For this
255 reason, usually granulomas are more localized. Conversely, in the effusive form,
256 pyogranulomas are more diffused and an antibody-dependent enhancement (ADE) mechanism
257 seem to promote inflammation (Paltrinieri et al., 2020). Since neutrophils and macrophages are
258 the ROS major producer, it is possible to conclude that, in the effusive form, a strong
259 inflammation together with marked oxidative stress lead to an evident decrease in PON-1
260 activity. The localization and amount of the granulomas could also have influenced the results.
261 As an example, one cat showed a PON-1 value that falls within the reference interval. In this
262 case, few IHC positive lesions were found in the cerebellum only. The strict localization and
263 the presence of the blood-brain barrier could explain a decreased strength and efficacy of the
264 immune response.

265

266 Finally, the analysis of the ROC curve demonstrated that PON-1 may differentiate cats

267 with FIP from cats without FIP but with similar clinical presentation. In a previous study,
268 performed with a different substrate, PON-1 was decreased in FIP cats compared to healthy
269 cats but no differences were observed with other inflammatory conditions (Tecles et al., 2015).
270 Based on sensitivity and specificity, cats with PON-1 values lower than 51.40 U/L have about
271 5 folds (LR+ = 4.65) probability to have FIP. However, this threshold is not clinically relevant,
272 because it includes several false positive and negative results. Given the emotional impact of
273 FIP diagnosis on cats' owners, it is relevant to minimize false positive results by increasing the
274 test specificity. A cut-off value of PON-1 equal to 24.90 U/L allows to maximize the specificity
275 (LR+ = 18.38; Sp = 97.6%; Se = 44.1%). Indeed, a cat with a PON-1 value lower than this
276 threshold had 18 folds the probability to be FIP affected. In this study, only 3/54 cats of the
277 NON FIP group had PON-1 values lower than this threshold. These cats had a septic effusion,
278 thus is not surprising to find a low value of PON-1 activity. However, in these cases, bacteria
279 microscopical observation in the effusion easily allows to rule out FIP. This cut-off could be
280 thus suggested when a confirmation of FIP is needed, considering that *in vivo* diagnosis is
281 sometimes challenging. On the contrary, when false negative results could impact the health
282 management of multcats environments (i.e. catteries) interfering with the identification of FIP
283 cats, a cut-off that maximize the sensitivity should be preferred. In this case, FIP should be
284 ruled out only in cats with PON-1 values higher than 78.30 U/L (LR- = 0; Se = 100%; Sp =
285 50%). This value falls inside the reference interval for PON-1 activity in the healthy population
286 (57.8 – 157.3 U/L; Rossi et al., 2020).

287

288 As already reported, the result of a single test is not sufficient to confirm FIP *in vivo*
289 (Tasker, 2018), especially without effusions. Results of this study show how PON-1
290 measurement is not an exception; nevertheless, very low PON-1 values could support the
291 suspicion of FIP. PON-1 measurement through a paraoxon based method is very easy to

292 perform and could be set out in every laboratory. Moreover, spectrophotometric evaluation
293 provides quicker results than the AGP immune radial diffusion. With respect of other methods
294 used for the measurement of PON-1, the paraoxon-based method gives results on a wider
295 numerical scale, allowing relevant clinical evaluations.

296

297 **Conclusions**

298 This study highlighted that PON-1 activity is a possible biomarker of FIP. Although the
299 good diagnostic performances obtained in this study, the association with other laboratory tests,
300 especially in dubious cases, is advisable. It could be interesting, in the future, to better
301 investigate the role on PON-1 in non-effusive FIP that were here underrepresented. Recent
302 developments in treatments against FIP (Addie et al., 2020; Dickinson et al., 2020) could also
303 add new perspectives on the role of PON-1 as a biomarker to monitor treatment efficacy.

304

305 **Acknowledgements**

306 We are grateful to the Pathology and Clinical Pathology staff of the University of
307 Padua for performing all the histology and immunohistochemistry.

308

309 Funding: This work was partially supported by the University of Milan [Fondo
310 Sviluppo UNIMI]. Preliminary results were presented as an Oral Presentation at the XVIII
311 ISACP Congress, Tokyo, 4th – 8th august 2018.

312

313 **Conflict of interest statement**

314 None of the authors has any financial or personal interest that could influence or bias
315 the content of the paper.

316

317 **References**

- 318 Addie, D., Belák, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-Jones, T.,
319 Hartmann, K., Hosie, M.J., Lloret, A., Lutz, H., Marsilio, F., Pennisi, M.G., Radford,
320 A.D., Thiry, E., Truyen, U., Horzinek, M.C. 2009. Feline infectious peritonitis. ABCD
321 guidelines on prevention and management. *Journal of Feline Medicine and Surgery*
322 11(7), 594-604. doi: 10.1016/j.jfms.2009.05.008.
- 323 Addie, D.D., Covell-ritchie, J., Jarrett, O., Fosbery, M., 2020. Rapid Resolution of Non-
324 Effusive Feline Infectious Peritonitis Uveitis with an Oral Adenosine Nucleoside
325 Analogue and Feline Interferon Omega. *Viruses* 12 (11), E1216.
- 326 Bojic, S., Kotur-Stevuljevic, J., Kalezic, N., Jelic-Ivanovic, Z., Stefanovic, A., Palibrk, I.,
327 Memon, L., Kalaba, Z., Stojanovic, M., Simic-Ogrizovic, S., 2014. Low paraoxonase-1
328 activity predicts mortality in surgical patients with sepsis. *Disease Markers* 2014(3):1–9.
329 <https://doi.org/10.1155/2014/427378>
- 330 Christenson, R.H., 2007. Evidence-based laboratory medicine - A guide for critical evaluation
331 of in vitro laboratory testing. *Annals of Clinical Biochemistry* 44, 111–130.
332 <https://doi.org/10.1258/000456307780118127>
- 333 Dickinson, P.J., Bannasch, M., Thomasy, S.M., Murthy, V.D., Vernau, K.M., Liepnieks, M.,
334 Montgomery, E., Knickelbein, K.E., Murphy, B., Pedersen, N.C., 2020. Antiviral
335 treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically
336 diagnosed neurological feline infectious peritonitis. *Journal of Veterinary Internal*
337 *Medicine* 34, 1587–1593. <https://doi.org/10.1111/jvim.15780>
- 338 Doenges, S.J., Weber, K., Dorsch, R., Fux, R., Hartmann, K., 2017. Comparison of real-time
339 reverse transcriptase polymerase chain reaction of peripheral blood mononuclear cells,
340 serum and cell-free body cavity effusion for the diagnosis of feline infectious peritonitis.
341 *Journal of Feline Medicine and Surgery* 19, 344–350.
342 <https://doi.org/10.1177/1098612X15625354>
- 343 Feingold, K.R., Memon, R.A., Moser, A.H., Grunfeld, C., 1998. Paraoxonase activity in the
344 serum and hepatic mRNA levels decrease during the acute phase response.
345 *Atherosclerosis* 139, 307–315. [https://doi.org/10.1016/S0021-9150\(98\)00084-7](https://doi.org/10.1016/S0021-9150(98)00084-7)
- 346 Felten, S., Hartmann, K., 2019. Diagnosis of Feline Infectious Peritonitis: A Review of the
347 Current Literature. *Viruses* 11(11):1068. doi: 10.3390/v11111068.
- 348 Felten, S., Leutenegger, C.M., Balzer, H.J., Pantchev, N., Matiasek, K., Wess, G., Egberink,
349 H., Hartmann, K., 2017. Sensitivity and specificity of a real-time reverse transcriptase
350 polymerase chain reaction detecting feline coronavirus mutations in effusion and
351 serum/plasma of cats to diagnose feline infectious peritonitis. *BMC Veterinary Research*
352 13, 1–11. <https://doi.org/10.1186/s12917-017-1147-8>
- 353 Furlong, C.E., Marsillach, J., Jarvik, G.P., Costa L.G. 2016. Paraoxonases-1, -2 and -3: What
354 are their functions? *Chemico-Biological Interaction* 259, 51-62. doi:
355 10.1016/j.cbi.2016.05.036.

- 356 Gardner, I.A., Greiner, M., 2006. Receiver-operating characteristic curves and likelihood
357 ratios: Improvements over traditional methods for the evaluation and application of
358 veterinary clinical pathology tests. *Veterinary Clinical Pathology* 35, 8–17.
359 <https://doi.org/10.1111/j.1939-165X.2006.tb00082.x>
- 360 Giordano, A., Stranieri, A., Rossi, G., Paltrinieri, S., 2015. High diagnostic accuracy of the
361 Sysmex XT-2000iV delta total nucleated cells on effusions for feline infectious
362 peritonitis. *Veterinary Clinical Pathology* 44, 295–302.
363 <https://doi.org/10.1111/vcp.12241>
- 364 Giordano, A., Veronesi, M.C., Rossi, G., Pezzia, F., Probo, M., Giori, L., Paltrinieri, S., 2013.
365 Serum paraoxonase-1 activity in neonatal calves: Age related variations and comparison
366 between healthy and sick animals. *The Veterinary Journal* 197, 499–501.
367 <https://doi.org/10.1016/j.tvjl.2013.01.034>
- 368 Giori, L., Giordano, A., Giudice, C., Grieco, V., Paltrinieri, S., 2011. Performances of
369 different diagnostic tests for feline infectious peritonitis in challenging clinical cases.
370 *Journal of Small Animal Practice* 52, 152–157. [https://doi.org/10.1111/j.1748-](https://doi.org/10.1111/j.1748-5827.2011.01042.x)
371 [5827.2011.01042.x](https://doi.org/10.1111/j.1748-5827.2011.01042.x)
- 372 Kennedy, M.A., 2020. Feline Infectious Peritonitis: Update on Pathogenesis, Diagnostics, and
373 Treatment. *Veterinary Clinics of North America Small Animals Practice* 50(5):1001-
374 1011. doi: 10.1016/j.cvsm.2020.05.002.
- 375 Khovidhunkit, W., Kim, M.S., Memon, R.A., Shigenaga, J.K., Moser, A.H., Feingold, K.R.,
376 Grunfeld, C., 2004. Effects of infection and inflammation on lipid and lipoprotein
377 metabolism: Mechanisms and consequences to the host. *Journal of Lipid Research* 45,
378 1169–1196. <https://doi.org/10.1194/jlr.R300019-JLR200>
- 379 Kipar, A., Meli, M.L., 2014. Feline Infectious Peritonitis: Still an Enigma? *Veterinary*
380 *Pathology* 51, 505–526. <https://doi.org/10.1177/0300985814522077>
- 381 Kumar, V., Fausto, N., Abbas, A.K., Aster, J.C., 2015. Cellular Responses to Stress and Toxic
382 Insults: Adaptation, Injury, and Death. In: Robbins and Cotran Pathologic basis of
383 disease, Ninth Edn. Elsevier, Philadelphia, PA, USA, pp. 31-68.
- 384 Montorfano, I., Becerra, A., Cerro, R., Echeverría, C., Sáez, E., Morales, M.G., Fernández,
385 R., Cabello-Verrugio, C., Simon, F., 2014. Oxidative stress mediates the conversion of
386 endothelial cells into myofibroblasts via a TGF- β 1 and TGF- β 2-dependent pathway.
387 *Laboratory Investigation* 94, 1068–1082. <https://doi.org/10.1038/labinvest.2014.100>
- 388 Paltrinieri, S., 2008. The feline acute phase reaction. *The Veterinary Journal* 177, 26–35.
389 <https://doi.org/10.1016/j.tvjl.2007.06.005>
- 390 Paltrinieri, S., Giordano, A., Stranieri, A., Lauzi, S., 2020. Feline infectious peritonitis (FIP)
391 and coronavirus disease 19 (COVID-19): Are they similar? *Transboundary and*
392 *Emerging Disease Online* ahead of print. <https://doi.org/10.1111/tbed.13856>
- 393 Paltrinieri, S., Giordano, A., Tranquillo, V., Guazzetti, S. 2007. Critical Assessment of the
394 Diagnostic Value of Feline α 1-Acid Glycoprotein for Feline Infectious Peritonitis Using

- 395 the Likelihood Ratios Approach. *Journal of Veterinary Diagnostic Investigation* 19, 266–
396 272. <https://doi.org/10.1177/104063870701900306>
- 397 Pedersen, N.C., 2014a. An update on feline infectious peritonitis: Virology and
398 immunopathogenesis. *The Veterinary Journal* 201, 123–132.
399 <https://doi.org/10.1016/j.tvjl.2014.04.017>
- 400 Pedersen, N.C., 2014b. An update on feline infectious peritonitis: Diagnostics and
401 therapeutics. *The Veterinary Journal* 201, 133–141.
402 <https://doi.org/10.1016/j.tvjl.2014.04.016>
- 403 Regan, A.D., Cohen, R.D., Whittaker, G.R. 2009. Activation of p38 MAPK by feline
404 infectious peritonitis virus regulates pro-inflammatory cytokine production in primary
405 blood-derived feline mononuclear cells. *Virology* 384(1), 135–43. doi:
406 10.1016/j.virol.2008.11.006.
- 407 Rossi, G., Giordano, A., Pezzia, F., Kjelgaard-Hansen, M., Paltrinieri, S., 2013. Serum
408 paraoxonase 1 activity in dogs: Preanalytical and analytical factors and correlation with
409 C-reactive protein and alpha-2-globulin. *Veterinary Clinical Pathology* 42, 329–341.
410 <https://doi.org/10.1111/vcp.12073>
- 411 Rossi, G., Ibba, F., Meazzi, S., Giordano, A., Paltrinieri, S., 2014. Paraoxonase activity as a
412 tool for clinical monitoring of dogs treated for canine leishmaniasis. *The Veterinary*
413 *Journal* 199, 143–149. <https://doi.org/10.1016/j.tvjl.2013.10.007>
- 414 Rossi, G., Meazzi, S., Giordano, A., Paltrinieri, S., 2020. Serum paraoxonase 1 activity in
415 cats: analytical validation, reference intervals, and correlation with serum amyloid A and
416 alpha-1-acid glycoprotein. *Journal of Veterinary Diagnostic Investigation*
417 <https://doi.org/10.1177/1040638720949638>
- 418 Ruggerone, B., Paltrinieri, S., Giordano, A., Scavone, D., Nocera, I., Rinnovati, R., Spadari,
419 A., Scacco, L., Pratelli, P., Sgorbini, M., 2020. Paraoxonase-1 activity evaluation as a
420 diagnostic and prognostic marker in horses and foals. *Journal of Veterinary Internal*
421 *Medicine* 34, 949–954. <https://doi.org/10.1111/jvim.15722>
- 422 Saunders, S. 2016. An update on feline infectious peritonitis. *Companion Animal* 21(8).
423 <https://doi.org/10.12968/coan.2016.21.8.472>
- 424 Shunmoogam, N., Naidoo, P., Chilton, R., 2018. Paraoxonase (PON)-1: A brief overview on
425 genetics, structure, polymorphisms and clinical relevance. *Vascular Health and Risk*
426 *Management* 14, 137–143. <https://doi.org/10.2147/VHRM.S165173>
- 427 Stranieri, A., Giordano, A., Paltrinieri, S., Giudice, C., Cannito, V., Lauzi, S. 2018.
428 Comparison of the performance of laboratory tests in the diagnosis of feline infectious
429 peritonitis. *Journal of Veterinary Diagnostic Investigation* 30(3), 459–463. doi:
430 10.1177/1040638718756460.
- 431 Stranieri, A., Paltrinieri, S., Giordano, A., 2017. Diagnosing feline infectious peritonitis using
432 the Sysmex XT-2000iV based on frozen supernatants from cavitory effusions. *Journal of*

- 433 Veterinary Diagnostic Investigation 29, 321–324.
434 <https://doi.org/10.1177/1040638716689115>
- 435 Stranieri, A., Scavone, D., Paltrinieri, S., Giordano, A., Bonsembiante, F., Ferro, S., Gelain,
436 M.E., Meazzi, S., Lauzi, S., 2020. Concordance between histology,
437 immunohistochemistry, and RT-PCR in the diagnosis of feline infectious peritonitis.
438 Pathogens 9, 1–15. <https://doi.org/10.3390/pathogens9100852>
- 439 Takano, T., Azuma, N., Satoh, M., Toda, A., Hashida, Y., Satoh, R., Hohdatsu, T., 2009.
440 Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by
441 macrophages in cats infected with feline infectious peritonitis virus contribute to the
442 pathogenesis of granulomatous lesions. Archives of Virology 154, 775–781.
443 <https://doi.org/10.1007/s00705-009-0371-3>
- 444 Tasker, S., 2018. Diagnosis of feline infectious peritonitis: Update on evidence supporting
445 available tests. Journal of Feline Medicine and Surgery 20, 228–243.
446 <https://doi.org/10.1177/1098612X18758592>
- 447 Tecles, F., Caldín, M., Tvarijonaviciute, A., Escribano, D., Martínez-Subiela, S., Cerón, J.J.,
448 2015. Serum biomarkers of oxidative stress in cats with feline infectious peritonitis.
449 Research in Veterinary Science 100, 12–17. <https://doi.org/10.1016/j.rvsc.2015.02.007>
- 450 Toyokuni, S., Okamoto, K., Yodoi, J., Hiai, H., 1995. Persistent oxidative stress in cancer.
451 FEBS Lett. 358, 1–3. [https://doi.org/10.1016/0014-5793\(94\)01368-B](https://doi.org/10.1016/0014-5793(94)01368-B)
- 452

453 **Table 1**

454 Breed, gender and median age of cats enrolled in the three groups. The median age is
 455 expressed in years.

Group	Breed	Gender	Median Age (Min - Max)
CNTR (<i>n</i> = 71)	DSH (<i>n</i> = 32), Ragdoll (<i>n</i> = 27), Maine Coon (<i>n</i> = 3), Sphynx (<i>n</i> = 3), British Shorthair (<i>n</i> = 1), Persian (<i>n</i> = 1), Siberian (<i>n</i> = 1), NR (<i>n</i> = 3)	F (<i>n</i> = 26), M (<i>n</i> = 43), NR (<i>n</i> = 3)	2 y (4 mo – 13 y)
NON FIP (<i>n</i> = 54)	DSH (<i>n</i> = 36), Maine Coon (<i>n</i> = 3), Ragdoll (<i>n</i> = 3), Bengal (<i>n</i> = 1), British Shorthair (<i>n</i> = 1), Exotic Shorthair (<i>n</i> = 1), Russian blue (<i>n</i> = 1), Sphynx (<i>n</i> = 1), NR (<i>n</i> = 8)	F (<i>n</i> = 21), M (<i>n</i> = 28), NR (<i>n</i> = 5)	8.5 y (4 mo – 19 y)
FIP (<i>n</i> = 34)	DSH (<i>n</i> = 23), British Shorthair (<i>n</i> = 2), Siberian (<i>n</i> = 2), Bengal (<i>n</i> = 1), Exotic Shorthair (<i>n</i> = 1), Persian (<i>n</i> = 1), Scottish fold (<i>n</i> = 1), Sphynx (<i>n</i> = 1), NR (<i>n</i> = 3)	F (<i>n</i> = 12), M (<i>n</i> = 19), NR (<i>n</i> = 4)	1 y (4 mo – 10 y)

456 DSH: domestic shorthair; F: female; M: male; mo: months; NR: not reported; y: years

457

458 **Table 2**

459 Laboratory results for cats with highly suspected FIP (PRESUMPTIVE FIP subgroup). All
 460 the cats had a cavitory effusion and severe clinical conditions that always ended in
 461 spontaneous death or euthanasia (Stranieri et al., 2018).

ID	LY	TP	ALB	A:G	SPE	AGP	PCR	ΔTNC	CYTO	OTHER
	(<1.5 *10 ⁶ /L)	(>80 g/L)	(<21 g/L)	(<0.8)		(>1.5 mg/mL)		(>2.5)		
126	X		X	X	X	X	X	X	X	J
127	X	X	X	X	X	X		X	X	
128	X		X	X	X			X	X	ICC ^b
129	X		X	X	X			X		
130		X	X	X	X	X		X	X	J, N
131		X	X	X			X	X	X	
132		X	X	X				X	X	J
134		X	X	X	X		X ^a		X	
135			X	X	X		X	X	X	N
136			X	X			X	X	X	N
137			X	X	X			X	X	N
138	X		X	X				X	X	
139	X		X	X	X			X	X	J, N

140	X		X	X	X		X	X
141	X	X	X	X	X			

462 LY: absolute lymphocyte count measured on peripheral blood; TP: serum total protein; ALB:
463 serum albumin; A:G: albumin to globulin ratio; SPE: serum protein electrophoresis; AGP:
464 serum alpha-1-acid glycoprotein; CYTO: effusion cytology, J: jaundice; N: necropsy.
465 ^a RT-PCR targeting the 3' UTR region was always performed on effusion except in this case,
466 in which it was performed on cerebrospinal fluid
467 ^b Immunocytochemistry was performed of effusion
468

469

470 **Figure legends**

471

472 Fig. 1. Paraoxonase (PON-1) activity (U/L) recorded in FIP, NON FIP and CNTR cats. The
473 boxes indicate the I–III interquartile range (IQR), the horizontal line indicates the median
474 values, whiskers extend to further observation within the I quartile minus $1.5 \times \text{IQR}$ or to further
475 observation within the III quartile plus $1.5 \times \text{IQR}$. The shaded area reported the reference interval
476 of PON-1 for healthy cats (Rossi et al., 2020).

477

478 Fig. 2. Results obtained from the comparison of the value of PON-1 (paraoxonase 1) activity
479 (U/L) among the subgroup of CONFIRMED, PRESUMPTIVE FIP, and groups NON FIP and
480 CNTR. The boxes indicate the I–III interquartile range (IQR), the horizontal line indicates the
481 median values, whiskers extend to further observation within the I quartile minus $1.5 \times \text{IQR}$ or
482 to further observation within the III quartile plus $1.5 \times \text{IQR}$. The shaded area reported the
483 reference interval of PON-1 for healthy cats (Rossi et al., 2020).

484


485 Fig. 3. Results obtained from the comparison of the value of PON-1 (paraoxonase 1) activity
486 (U/L) among the subgroup of DRY FIP, WET FIP and the groups NON FIP and CNTR. The
487 boxes indicate the I–III interquartile range (IQR), the horizontal line indicates the median
488 values, whiskers extend to further observation within the I quartile minus $1.5 \times \text{IQR}$ or to further
489 observation within the III quartile plus $1.5 \times \text{IQR}$. The shaded area reported the reference interval
490 of PON-1 for healthy cats (Rossi et al., 2020).

491

492 Fig. 4. Receiver Operating Characteristic (ROC) curve built using the values of PON-1
493 (paraoxonase 1) activity (U/L) for the diagnosis of FIP. The central line represents the no-
494 discrimination line.

Figure 1


[Click here to access/download;Figure;Fig.1.tif](#)



Livello incollato

Figure 2


[Click here to access/download;Figure;Fig.2.tif](#)



Livello incollato

Figure 3


[Click here to access/download;Figure;Fig.3.tif](#)



Livello incollato

Figure 4

[Click here to access/download;Figure;Fig.4.tif](#)



Livello incollato

Highlights

- Feline infectious peritonitis is associated with strong inflammation and oxidation
- Paraoxonase-1 (PON-1) is an antioxidant and a negative acute phase reactant
- PON-1 activity lowest values were observed in cats with FIP
- PON-1 seems accurate in discriminating FIP from other similar clinical conditions
- Measurement of PON-1 activity could serve as a possible biomarker of FIP

Dear Editor,

the manuscript here enclosed and titled 'Role of paraoxonase-1 (PON-1) as a diagnostic marker for feline infectious peritonitis (FIP)' is submitted to be considered for publication on *The Veterinary Journal*

The manuscript has been reviewed by an English-speaking scientist and a thorough format editing has been performed before submission in order to comply with journal guidelines.

I would certify that the manuscript has not be submitted to other Journals. Preliminary results of this study were presented at the XVIIIth ISACP (International Society for Animal Clinical Pathology) annual congress in Tokyo, 4-8th August, 2018.

Sincerely,
Angelica Stranieri